Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Research & Development: 2009-2024

Historic Research & Development for Corcept Therapeutics (CORT) over the last 12 years, with Dec 2024 value amounting to $246.9 million.

  • Corcept Therapeutics' Research & Development rose 16.03% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.4 million, marking a year-over-year increase of 12.56%. This contributed to the annual value of $246.9 million for FY2024, which is 33.92% up from last year.
  • Corcept Therapeutics' Research & Development amounted to $246.9 million in FY2024, which was up 33.92% from $184.4 million recorded in FY2023.
  • Over the past 5 years, Corcept Therapeutics' Research & Development peaked at $246.9 million during FY2024, and registered a low of $113.9 million during FY2021.
  • Moreover, its 3-year median value for Research & Development was $184.4 million (2023), whereas its average is $187.4 million.
  • Per our database at Business Quant, Corcept Therapeutics' Research & Development dropped by 0.78% in 2021 and then soared by 40.74% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Research & Development (Yearly) stood at $114.8 million in 2020, then declined by 0.78% to $113.9 million in 2021, then climbed by 15.04% to $131.0 million in 2022, then spiked by 40.74% to $184.4 million in 2023, then soared by 33.92% to $246.9 million in 2024.